Menu
← Oncology Approval Tracker
FDA DECISION ·
Rituxan + chemotherapy
rituximab with chemotherapy · Genentech
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Children aged 6 months to under 18 years with previously untreated, advanced CD20-positive DLBCL, Burkitt or Burkitt-like lymphoma, or mature B-cell acute leukemia.
LAMPGEN ANALYSIS
Why it matters
This adds rituximab to chemotherapy for specified pediatric CD20-positive malignancies.
What research teams should watch
Document CD20 result, histology, stage and age, and coordinate infusion reactions and infection surveillance.
PRIMARY RECORDS